Skip to content
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
Archyde

Archyde

  • News
  • World
  • Economy
  • Technology
  • Health
  • Entertainment
  • Sport

Jideytro

FDA Approves GSK Jideytro for ROS1-Positive Non-Small Cell Lung Cancer

FDA Approves GSK Jideytro for ROS1-Positive Non-Small Cell Lung Cancer

September 15, 2026 by Dr. Priya Deshmukh - Senior Editor, Health

The U.S.

Categories Health Tags ARROS-1 phase I/II trial, Food and Drug Administration, GSK plc, Jideytro, Nuvalent Inc, Real-Time Oncology Review, ROS1-positive non-small cell lung cancer Leave a comment

Recent Posts

  • ESA’s Cluster Satellite Tango Reenters Over South Pacific
  • Eva Bargiela’s Blind Sister: Struggling with Debt and Poverty
  • Knoxville Tennessee Temple Set for March 2027 Dedication
  • Arizona Secretary of State Adrian Fontes Addresses Mail-In Voting Security
  • Jeonnam-Gwangju Firefighters Placed on Leave After Gambling at Integrity Workshop
  • Latest News
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Terms and Conditions
  • About Us
© 2026 Archyde — All Rights Reserved. Contact | Privacy Policy